2023
Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations.
Feng M, Prajapati S, Castro D, Lee K, Chan E, Sehgal I, Patel J, O'Dell A, Zengin Z, Li X, Chehrazi-Raffle A, Dizman N, Tripathi A, Rock A, Liu S, Mercier B, Meza L, Philip E, Dorff T, Pal S. Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations. Journal Of Clinical Oncology 2023, 41: 34-34. DOI: 10.1200/jco.2023.41.6_suppl.34.Peer-Reviewed Original ResearchType of treatmentExclusion criteriaBrain metastasesEligibility criteriaExact testHBV/HCVMetastatic prostate cancerFisher's exact testChi-square testClinical eligibilityConcurrent malignancyHCV positivityHormone therapyHIV positivityCombination therapyRadioligand therapyClinical trialsProstate cancerProstate cancer studyRadiation therapyClinical OncologyTherapyCancer typesMeSH termsPhase IAssessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations.
Castro D, Feng M, Prajapati S, Chan E, Lee K, Sehgal I, Patel J, O'Dell A, Zengin Z, Li X, Chehrazi-Raffle A, Dizman N, Tripathi A, Rock A, Liu S, Mercier B, Meza L, Philip E, Dorff T, Pal S. Assessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations. Journal Of Clinical Oncology 2023, 41: 453-453. DOI: 10.1200/jco.2023.41.6_suppl.453.Peer-Reviewed Original ResearchHIV positivityHCV positivityEligibility criteriaCancer trialsExclusion criteriaConcurrent malignancyBrain metastasesCombination therapyExact testClass of therapyTrial eligibility criteriaReal-world populationFisher's exact testRestrictive eligibility criteriaSpecific study populationMultiple cancer typesChemotherapy trialsReal-world practiceInvestigational treatmentStudy populationRadiation therapyClinical OncologyPrognostic toolTherapySignificant associationEvaluation of eligibility criteria in contemporary renal cell carcinoma based on ASCO-FCR recommendations.
Prajapati S, Feng M, Castro D, Lee K, Chan E, Sehgal I, Patel J, O'Dell A, Zengin Z, Li X, Chehrazi-Raffle A, Dizman N, Tripathi A, Rock A, Liu S, Mercier B, Meza L, Philip E, Dorff T, Pal S. Evaluation of eligibility criteria in contemporary renal cell carcinoma based on ASCO-FCR recommendations. Journal Of Clinical Oncology 2023, 41: 612-612. DOI: 10.1200/jco.2023.41.6_suppl.612.Peer-Reviewed Original ResearchRestrictive eligibility criteriaEligibility criteriaHCV positivityHIV positivityInclusion criteriaExclusion criteriaExact testClass of therapyReal-world populationRenal cell carcinomaFisher's exact testChi-square testConcurrent malignancyBrain metastasesAdult patientsCell carcinomaCombination therapyPatient populationCancer trialsRCC trialsConsensus statementRadiation therapyClinical OncologyPrognostic toolReal-world settingGenomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma
Zengin Z, Govindarajan A, Salgia N, Sayegh N, Tripathi N, Muddasani R, Chehrazi-Raffle A, Feng M, Mercier B, Ladbury C, Hao C, Salgia S, Chawla N, Meza L, Malhotra J, Dizman N, Hsu J, Castro D, Barragan-Carrillo R, Ebrahimi H, Philip E, Chang M, Zhang J, Byron S, Lyou Y, Dorff T, Pal S, Dandapani S. Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma. European Urology Oncology 2023, 6: 447-450. PMID: 36609061, DOI: 10.1016/j.euo.2022.11.006.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaStereotactic body radiation therapyRenal cell carcinomaBody radiation therapyCell carcinomaRadiation therapyClear cell renal cell carcinomaFirst-line treatmentCell renal cell carcinomaStereotactic body radiotherapyKidney cancer patientsOligoprogressive diseaseSystemic treatmentReactive oxygen species pathwayBody radiotherapyCancer patientsTreatment selectionPatientsTreatment changesOxygen species pathwayRadiation treatmentCarcinomaCell proliferationPotential roleRadiotherapy
2022
Transcriptomic profiling identifies genomic markers associated with benefit from stereotactic body radiation therapy (SBRT) in oligoprogressive metastatic renal cell carcinoma (mRCC).
Zengin Z, Govindarajan A, Muddasani R, Salgia N, Sayegh N, Tripathi N, Salgia S, Meza L, Zhang J, Chawla N, Chehrazi-Raffle A, Malhotra J, Dizman N, Hsu J, Castro D, Byron S, Dandapani S, Pal S. Transcriptomic profiling identifies genomic markers associated with benefit from stereotactic body radiation therapy (SBRT) in oligoprogressive metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2022, 40: 4555-4555. DOI: 10.1200/jco.2022.40.16_suppl.4555.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaStereotactic body radiation therapySystemic treatmentSystemic therapyLess benefitCompletion of SBRTRole of SBRTHigh expressionBody radiation therapyRenal cell carcinomaT-testStudent's t-testHypoxia-related genesCommon histologyOligoprogressive diseaseClinicopathologic characteristicsMedian ageFischer's exactClinical benefitCell carcinomaClear cellsRadiation therapyTreatment durationTreatment changesIncreased expression